BNZ132-1-40

DRUG3 trials

Sponsors

Bioniz Therapeutics

Conditions

CTCLHealthyLGL LeukemiaSafety and Tolerability in Healthy Subjects

Phase 1

A First-in-Human Study of BNZ132-1-40

CompletedNCT03046459

Bioniz TherapeuticsHealthy

Start: 2016-11-30End: 2017-06-05Updated: 2017-06-22

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

CompletedNCT03239379

Bioniz TherapeuticsSafety and Tolerability in Healthy Subjects

Start: 2017-10-30End: 2018-03-08Updated: 2018-05-15

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

CompletedNCT03239392

Bioniz TherapeuticsCTCL, LGL Leukemia

Start: 2018-04-01End: 2020-06-30Updated: 2021-05-25

Related Papers

KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia

Cell Reports Medicine2025-03-272 citations

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Blood2023-06-2417 citations

Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias

HemaSphere2021-06-015 citations

Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial

Blood2020-11-043 citations

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Blood2019-11-13

B-102 Results from a First-In-Human study with BNZ-1, a novel, selective inhibitor of IL-2, IL-9, and IL-15 at the common gamma-chain receptor, in clinical development for the treatment of HAM/TSP and T-cell malignancies

JAIDS Journal of Acquired Immune Deficiency Syndromes2018-04-011 citations

Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+ Central Memory T-Cells

Blood2017-12-075 citations